Ipamorelin – Research Peptide

Ipamorelin is a synthetic pentapeptide belonging to the growth hormone secretagogue (GHS) family. It was developed as a highly selective agonist of the growth hormone secretagogue receptor (GHSR-1a) with the goal of stimulating endogenous growth hormone (GH) release while minimizing activity on other endocrine pathways. Due to its receptor selectivity, Ipamorelin has become an important investigational compound in endocrinology, metabolism, body composition, and regenerative physiology research.

Unlike earlier growth hormone secretagogues, Ipamorelin demonstrates a high degree of specificity for GHSR-1a and has shown minimal effects on cortisol, prolactin, and adrenocorticotropic hormone (ACTH) secretion in many experimental studies. This selective pharmacological profile has contributed to its widespread use in laboratory research exploring pulsatile growth hormone release and insulin-like growth factor-1 (IGF-1) physiology.

Although the biological mechanisms of Ipamorelin have been well characterized in preclinical and early clinical studies, further human research is required to better define its long-term physiological effects and broader research applications.

Research Overview

Growth hormone secretion is regulated by a complex interaction between growth hormone-releasing hormone (GHRH), somatostatin, and the hormone ghrelin, which acts through the growth hormone secretagogue receptor.

Ipamorelin was developed to selectively activate this receptor, thereby stimulating endogenous growth hormone release while preserving the body’s normal physiological feedback mechanisms. Unlike administration of exogenous growth hormone, stimulation through GHSR-1a produces pulsatile GH secretion that remains subject to hypothalamic regulation.

Because of these characteristics, Ipamorelin has become a valuable research tool for investigating growth hormone physiology, endocrine regulation, muscle biology, tissue repair, and healthy aging.

Mechanism of Action

Ipamorelin exerts its biological effects primarily through selective activation of the growth hormone secretagogue receptor (GHSR-1a).

Growth Hormone Secretagogue Receptor Activation

Following receptor binding, Ipamorelin stimulates somatotroph cells within the anterior pituitary gland to release endogenous growth hormone.

Unlike direct administration of recombinant GH, this mechanism maintains the body’s natural regulatory control over hormone secretion.

Growth Hormone and IGF-1 Axis

The increase in endogenous GH stimulates production of insulin-like growth factor-1 (IGF-1), primarily within the liver and peripheral tissues.

The GH/IGF-1 axis plays an important physiological role in:

• Protein metabolism
• Skeletal muscle biology
• Bone remodeling
• Connective tissue maintenance
• Cellular growth and repair

These pathways continue to be investigated across multiple research disciplines.

Endocrine Selectivity

One distinguishing feature of Ipamorelin is its relative selectivity for growth hormone secretion.

Experimental studies have generally demonstrated minimal stimulation of:

• Cortisol
• Prolactin
• ACTH

compared with earlier generations of growth hormone secretagogues.

Ghrelin Signaling

Because GHSR-1a is also the endogenous receptor for ghrelin, Ipamorelin provides researchers with an experimental model for studying ghrelin-mediated endocrine signaling independently of many of ghrelin’s broader physiological effects.

Current Scientific Research

Ipamorelin has been investigated through laboratory studies, animal models, and early-phase human clinical trials.

Endocrinology Research

Much of the published literature has focused on the regulation of pulsatile growth hormone secretion and the physiological characteristics of selective GHSR activation.

These investigations have contributed significantly to understanding endocrine feedback mechanisms governing GH release.

Muscle and Connective Tissue Biology

Researchers continue to evaluate the influence of endogenous GH stimulation on:

• Skeletal muscle physiology
• Connective tissue remodeling
• Recovery following experimental injury
• Protein metabolism

Further investigation is needed to clarify the relative contributions of GH and IGF-1 to these biological processes.

Healthy Aging Research

Because endogenous growth hormone production naturally declines with age, Ipamorelin has become an experimental tool for studying age-related endocrine changes and their effects on body composition and tissue maintenance.

Combination Peptide Research

Ipamorelin is frequently investigated alongside growth hormone-releasing hormone analogs such as CJC-1295 to examine complementary regulation of the GH axis. Ongoing research seeks to better characterize how these pathways interact under physiological conditions.

Potential Research Applications

Current scientific literature is investigating Ipamorelin in relation to:

• Growth hormone physiology
• IGF-1 regulation
• Endocrine signaling
• Skeletal muscle biology
• Protein metabolism
• Connective tissue research
• Healthy aging
• Body composition
• Regenerative physiology

These represent active areas of scientific investigation and should not be interpreted as established therapeutic indications.

Product Snapshot

Research Category: Growth Hormone Secretagogue

Alternative Name: NNC-26-0161

Primary Molecular Target:

• Growth Hormone Secretagogue Receptor (GHSR-1a)

Research Administration Route: Experimental laboratory use

Development Status: Extensive preclinical and early clinical research

Evidence Strength: ★★★★☆

Strong mechanistic evidence supported by animal studies and multiple early-phase human investigations examining endocrine physiology.

Key Scientific References

Raun K, Hansen BS, Johansen PB, et al. Ipamorelin, the First Selective Growth Hormone Secretagogue. European Journal of Endocrinology.

A landmark publication describing the pharmacological development of Ipamorelin and demonstrating its selective stimulation of endogenous growth hormone release.

Jørgensen JOL, et al. Growth Hormone Secretagogues in Human Physiology and Clinical Investigation. Clinical Endocrinology.

A comprehensive review examining growth hormone secretagogues, including Ipamorelin, with emphasis on endocrine regulation, receptor pharmacology, and physiological responses.

Smith RG, Van der Ploeg LHT, Howard AD, et al. Peptidomimetic Regulation of Growth Hormone Secretion Through the Ghrelin Receptor. Endocrine Reviews.

An authoritative review detailing GHSR biology, ghrelin signaling, and the development of selective growth hormone secretagogues.

Bowers CY. Growth Hormone-Releasing Peptides and Their Receptors. Endocrine.

A foundational review describing the discovery, pharmacology, and physiological significance of growth hormone secretagogues, including Ipamorelin.

PubMed – Ipamorelin Research

A continually updated collection of peer-reviewed publications examining Ipamorelin across endocrinology, growth hormone physiology, metabolism, healthy aging, and regenerative research.

Research Use Statement

For Research Use Only.

Ipamorelin supplied by Performance Pharma is intended exclusively for laboratory and scientific research conducted by qualified professionals. This product is not approved for human or veterinary use and is not intended to diagnose, treat, cure, or prevent any disease. It should be handled, stored, and used in accordance with applicable laws, regulations, and accepted laboratory research practices.